IP Library Granted Patent US 10,465,181
Granted Patent B2
US 10,465,181 · App. 15/884,449 · Granted Nov 5, 2019

Mutations in iron-sulfur cluster proteins that improve xylose utilization

Inventors: Allan Froehlich (Hartland, VT); Brooks Henningsen (Lebanon, NH); Sean Covalla (Thetford Center, VT); Rintze M. Zelle (Lebanon, NH)
Assignee: Lallemand Hungary Liquidity Management LLC
C12N9/92C07K14/395C12P7/06C12Y503/01005Y02E50/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,465,181
App. No.
15/884,449
Granted
Nov 5, 2019
Kind
B2
Abstract

There is provided an engineered host cells comprising (a) one or more mutations in one or more endogenous genes encoding a protein associated with iron metabolism; and (b) at least one gene encoding a polypeptide having xylose isomerase activity, and methods of their use thereof.

Claims (21)

1. A recombinant yeast cell comprising (a) at least one heterologous gene encoding a protein associated with iron metabolism; and (b) at least one heterologous gene encoding a polypeptide having xylose isomerase activity, wherein the heterologous gene (b) encodes a polypeptide having at least 80%, 85%, 90%, 95% or 100% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 35, 37, 39 and 41.

2. The recombinant yeast cell of claim 1 , wherein the heterologous gene (a) is selected from the group consisting of AFT1, AFT2, and orthologues and combinations thereof.

3. The recombinant yeast cell of claim 1 , wherein heterologous gene (a) encodes a protein that increases the activity of Aft1 and/or Aft2 and/or increases the expression of AFT1 and/or AFT2 and/or suppresses or inhibits the activity and/or expression of a protein that suppresses or inhibits the activity of Aft1 and/or Aft2 and/or suppresses or inhibits the expression of AFT1 and/or AFT2.

4. The recombinant yeast cell of claim 1 , wherein the heterologous gene encodes a target of Aft1 and/or Aft2.

5. The recombinant yeast cell of claim 1 , wherein the heterologous gene (a) encodes a polypeptide having iron transport activity.

6. The recombinant yeast cell of claim 1 , the recombinant yeast cell further comprises one or more mutations in one or more endogenous genes encoding a protein associated with iron metabolism.

7. The recombinant yeast cell of claim 6 , wherein the one or more mutations in one ore more endogenous genes is in a gene of ISU1, YFH1, NFS1, AFT1, AFT2, YAP5, FRA1, FRA2, GREX3, GREX4, CCC1, or any combination thereof.

8. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell comprises one or more mutations in the endogenous ISU1 gene that results in a polypeptide comprising at least one amino acid substitution selected from the group consisting of D71N, D71G, and S98F, wherein the position of the substitution is relative to the amino acid positions of SEQ ID NO:29.

9. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell comprises one or more mutations in the endogenous YFH1 gene that results in a polypeptide comprising a T163P substitution, wherein the position of the substitution is relative to the amino acid positions of SEQ ID NO:31.

10. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell comprises one or more mutations in the endogenous NFS1 gene that results in a polypeptide comprising at least one amino acid substitution selected from the group consisting of L115W and E458D, wherein the position of the substitution is relative to the amino acid positions of SEQ ID NO:33.

11. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell comprises a mutation in the endogenous AFT1 gene that results in increased Aft1 activity and/or a mutation in the endogenous AFT2 gene that results in increased Aft2 activity.

12. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell comprises one or more mutations in one or more endogenous genes FRA1, FRA2, GREX3, or GREX4; wherein the one or more mutations results in increased activity of Aft1 and/or Aft2; and/or wherein the one or more mutations results in increased expression of one or more genes regulated by Aft1 and/or Aft2.

13. The recombinant yeast cell of claim 6 , wherein the recombinant yeast cell further comprises a mutation in an endogenous gene selected from the group consisting of YAP5 and CCC1.

14. The recombinant yeast cell of claim 1 , wherein the recombinant yeast cell further comprises at least one genetic modification of one or more endogenous genes encoding a protein of the pentose phosphate pathway.

15. The recombinant yeast cell of claim 14 , wherein the recombinant, yeast cell comprises at least one genetic modification in at least one of the endogenous genes selectec the group consisting of XKS1, RKI1, RPE1, TKL1, and TAL1.

16. The recombinant yeast cell of claim 1 , wherein the recombinant yeast cell further comprises a deletion or disruption of one or more aldose reductase genes.

17. The recombinant yeast cell of claim 16 , wherein the aldose reductase gene is GRE3 or YPR1.

18. The recombinant yeast cell of any one of claim 17 , wherein the yeast cell further comprises a modification of the endogenous PGM1 gene.

19. The recombinant yeast cell of claim 1 , wherein the recombinant yeast cell comprises heterologous expression of one or more polynucleotides encoding XKS1, RKI1, RPE1, TKL1, and/or TAL1.

20. The recombinant yeast cell of claim 1 , wherein the heterologous gene (b) encodes a polypeptide having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, and 27.

21. A method for producing a fermentation product comprising contacting the recombinant yeast cell of claim 1 with a carbon source, wherein said carbon source comprises xylose and/or xylan.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2024
From: LALLEMAND HUNGARY LIQUIDITY MANAGEMENT LLC
To: DANSTAR FERMENT AG
Reel/Frame 068174/0430 →
CHANGE OF ADDRESS Recorded Jul 12, 2024
From: LALLEMAND HUNGARY LIQUIDITY MANAGEMENT LLC
To: LALLEMAND HUNGARY LIQUIDITY MANAGEMENT LLC
Reel/Frame 068312/0431 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2019
From: FROEHLICH, ALLAN; HENNINGSEN, BROOKS; COVALLA, SEAN; ZELLE, RINTZE M
To: LALLEMAND HUNGARY LIQUIDITY MANAGEMENT LLC
Reel/Frame 050799/0064 →
Continuity (3)
Continuation 14821955 · Aug 10, 2015
Provisional Application 62035748 · Aug 11, 2014
Related Publication 20180251750A1 · Sep 6, 2018